Basiliximab for IL-2-Associated Inflammatory Disorder With Atopic Dermatitis.

IF 1.2 4区医学 Q3 DERMATOLOGY

Pediatric Dermatology Pub Date : 2025-02-25 DOI:10.1111/pde.15913

Sarah L Becker, Liza Kenny, Alison Small

引用次数: 0

Abstract

Options for pediatric patients with severe atopic dermatitis who do not respond to biologics remain limited. We report the case of a 10-year-old boy with severe, recalcitrant atopic dermatitis associated with episodic fever, joint pains, and elevated serum IL-2R, which responded to basiliximab. To our knowledge, this is the first reported use of basiliximab for atopic dermatitis in a pediatric patient. This case highlights the potential for basiliximab as a therapy for severe cases of atopic dermatitis and the potential for precision medicine in dermatology.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

6.70%

发文量

269

审稿时长

1 months

期刊介绍： Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.